Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2019
gptkb:European_Union gptkb:United_States |
| gptkbp:bioavailability |
approximately 80%
|
| gptkbp:casnumber |
56392-17-7
|
| gptkbp:chemical_formula |
C19 H22 N2 O4 S
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:developed_by |
gptkb:Pfizer
|
| gptkbp:formulation |
gptkb:Software_Solutions
gptkb:capsule |
| https://www.w3.org/2000/01/rdf-schema#label |
tafamidis
|
| gptkbp:indication |
gptkb:h_ATTR_amyloidosis
|
| gptkbp:marketed_as |
gptkb:Vyndamax
gptkb:Vyndaqel |
| gptkbp:mechanism_of_action |
stabilizes transthyretin protein
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
fatigue
headache nausea diarrhea |
| gptkbp:used_for |
gptkb:transthyretin_amyloidosis
|
| gptkbp:bfsParent |
gptkb:Transthyretin_amyloidosis
|
| gptkbp:bfsLayer |
6
|